LYEL
NASDAQ · Biotechnology
Lyell Immunopharma Inc
$20.89
+1.19 (+6.04%)
Financial Highlights (FY 2026)
Revenue
98.3K
Net Income
-548,444,051
Gross Margin
—
Profit Margin
-562,285.3%
Rev Growth
-82.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 29.6% | 29.6% |
| Operating Margin | -609,436.1% | -548,493.3% | -16.0% | -15.0% |
| Profit Margin | -562,285.3% | -534,171.0% | -14.9% | -15.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 98.3K | 549.2K | 107.82M | 110.08M |
| Gross Profit | — | — | 31.94M | 32.61M |
| Operating Income | -598,795,316 | -3,012,385,603 | -17,264,565 | -16,469,755 |
| Net Income | -548,444,051 | -2,759,081,307 | -16,079,673 | -17,508,845 |
| Gross Margin | — | — | 29.6% | 29.6% |
| Operating Margin | -609,436.1% | -548,493.3% | -16.0% | -15.0% |
| Profit Margin | -562,285.3% | -534,171.0% | -14.9% | -15.9% |
| Rev Growth | -82.1% | -82.1% | +2.1% | -2.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 170.75M | 218.79M |
| Total Equity | — | — | 336.15M | 314.14M |
| D/E Ratio | — | — | 0.51 | 0.70 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -555,539,280 | -2,950,040,894 | -19,078,562 | -20,059,530 |
| Free Cash Flow | — | — | -8,704,547 | -8,409,186 |